Ischaemic Heart Disease: A Secondary Prevention Trial Using Clofibrate

,

doi:10.1136/bmj.4.5790.775

BMJ

1971

DOI: 10.1136/bmj.4.5790.775

|View full text |Cite

Ischaemic Heart Disease: A Secondary Prevention Trial Using Clofibrate

Abstract: Industries Limited, who, with other members of his medical and statistical team, has gone to endless trouble over the analysis of results.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1992

2016

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 212 publications

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Statins and fibrates for preventing melanoma

Dellavalle

Drake

Graber

et al. 2005

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

The melanoma outcomes data collected in this review of RCTs of statins and fibrates does not exclude the possibility that these drugs prevent melanoma. There was a 10% and 42% reduction for participants on statins and fibrates, respectively, however these results were not statistically significant. Until further evidence is established, limiting exposure to ultraviolet radiation remains the most effective way to reduce the risk of melanoma.

show abstract

Statins and fibrates for preventing melanoma

Dellavalle

Drake

Graber

et al. 2005

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Fibrates for secondary prevention of cardiovascular disease and stroke

Wang

Liu

Tao

et al. 2015

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Fibrates are a class of drugs characterised by mainly lowering high triglyceride, raising high-density lipoprotein (HDL) cholesterol, and lowering the small dense fraction of low-density lipoprotein (LDL) cholesterol. Their e icacy for secondary prevention of serious vascular events is unclear, and to date no systematic review focusing on secondary prevention has been undertaken. Objectives To assess the e icacy and safety of fibrates for the prevention of serious vascular events in people with previous cardiovascular disease (CVD), including coronary heart disease and stroke.

show abstract

Fibrates for primary prevention of cardiovascular disease events

Jakob

Nordmann

Schandelmaier

et al. 2016

Cochrane Database of Systematic Reviews

105

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Ischaemic Heart Disease: A Secondary Prevention Trial Using Clofibrate

Abstract: Industries Limited, who, with other members of his medical and statistical team, has gone to endless trouble over the analysis of results.

Cited by 212 publications

References 11 publications

Statins and fibrates for preventing melanoma

Statins and fibrates for preventing melanoma

Fibrates for secondary prevention of cardiovascular disease and stroke

Fibrates for primary prevention of cardiovascular disease events

Contact Info

Product

Resources

About